45.59

1.34% -0.62

Tarsus Pharmaceuticals Inc (TARS)

Overview News Price History Option Chain Financials Discussions Forecast

Tarsus Pharmaceuticals Inc stock is traded at $45.59, with a volume of 436.73K. It is down -1.34% in the last 24 hours and up +34.52% over the past month. Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.

Previous Close:

$46.21

Open:

$45.03

24h Volume:

436.73K

Relative Volume:

0.61

Market Cap:

$1.76B

Revenue:

$17.39M

Net Income/Loss:

$-135.89M

P/E Ratio:

-13.49

EPS:

-3.38

Net Cash Flow:

$-123.00M

1W Performance:

+3.92%

1M Performance:

+34.52%

6M Performance:

+23.72%

1Y Performance:

+184.94%

1-Day Range:

$43.77

$47.06

1-Week Range:

$42.21

$48.60

52-Week Range:

$15.47

$48.60

Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile

Name

Tarsus Pharmaceuticals Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

(949) 409-9820

Address

15440 LAGUNA CANYON ROAD, IRVINE

Employee

244

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

TARS's Discussions on Twitter

Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-20-23	Initiated	Goldman	Neutral
Jul-18-23	Initiated	William Blair	Outperform
May-18-23	Initiated	Guggenheim	Buy
Aug-01-22	Initiated	Barclays	Overweight
Dec-21-21	Initiated	H.C. Wainwright	Buy
Nov-23-21	Initiated	Oppenheimer	Outperform
Nov-10-20	Initiated	BofA Securities	Buy
Nov-10-20	Initiated	Jefferies	Buy
Nov-10-20	Initiated	Ladenburg Thalmann	Buy
Nov-10-20	Initiated	Raymond James	Strong Buy

View All

Tarsus Pharmaceuticals Inc Stock (TARS) Latest News

08:33 AM

Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer - GlobeNewswire

08:33 AM

06:46 AM

Here's Why Tarsus Pharmaceuticals (NASDAQ:TARS) Can Manage Its Debt Despite Losing Money - Simply Wall St

06:46 AM

03:51 AM

Vanguard Group Inc's Strategic Acquisition in Tarsus Pharmaceuti - GuruFocus.com

03:51 AM

Nov 04, 2024

Emerald Mutual Fund Advisers Trust Acquires New Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat

Nov 04, 2024

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Rating of "Buy" by Analysts - MarketBeat

Nov 04, 2024

Nov 01, 2024

Tarsus Pharmaceuticals (NASDAQ:TARS) Trading Up 8.5%What's Next? - MarketBeat

Nov 01, 2024

Tarsus Pharmaceuticals (TARS) Surges 10.6%: Is This an Indication of Further Gains? - MSN

Nov 01, 2024

Oct 30, 2024

Tarsus Pharmaceuticals stock hits 52-week high at $42.63 By Investing.com - Investing.com Australia

Oct 30, 2024

Oct 29, 2024

Tarsus Pharmaceuticals (NASDAQ:TARS) Sets New 52-Week HighShould You Buy? - MarketBeat

Oct 29, 2024

Tarsus Pharmaceuticals stock hits 52-week high at $42.63 - Investing.com

Oct 29, 2024

Oct 28, 2024

Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap UpHere's Why - MarketBeat

Oct 28, 2024

Allspring Global Investments Holdings LLC Buys 29,465 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat

Oct 28, 2024

Oct 25, 2024

Assenagon Asset Management S.A. Raises Stock Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat

Oct 25, 2024

Oct 17, 2024

Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY - The Bakersfield Californian

Oct 17, 2024

Tarsus Launches “Your Mitey Problem,” the First - GlobeNewswire

Oct 17, 2024

Tarsus Pharmaceuticals, Inc Announces the Launch of New Direct-To-Consumer TV campaign for XDEMVY - Marketscreener.com

Oct 17, 2024

Oct 13, 2024

Essex Investment Management Co. LLC Invests $3.59 Million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat

Oct 13, 2024

Oct 11, 2024

Was Tarsus Pharmaceuticals Inc (TARS)’s session last reading good? - US Post News

Oct 11, 2024

Financial Analysis: Tarsus Pharmaceuticals Inc (TARS)’s Ratios Unveil Key Insights - The Dwinnex

Oct 11, 2024

Oct 10, 2024

Taking a look at what insiders are doing to gauge the Tarsus Pharmaceuticals Inc (TARS)’s direction - Knox Daily

Oct 10, 2024

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives $51.60 Consensus Price Target from Analysts - MarketBeat

Oct 10, 2024

Oct 09, 2024